Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00665802PMID 8251649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression

  1991cited by this paper
• Expression of messenger RNAs for platelet‐derived growth factor and its receptors in human sarcoma cell lines

  1990cited by this paper
• Expression of PDGF β‐receptors in human meningioma cells

  1990cited by this paper
• Expression of PDGF beta-receptors in human meningioma cells.

  1990cited by this paper
• Platelet‐derived growth factor and its receptor in blood cell differentiation and neoplasia

  1990cited by this paper
• Expression of several growth factors and their receptor genes in human colon carcinomas

  1990cited by this paper
• Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis.

  1989cited by this paper
• Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma).

  1989cited by this paper
• Transforming Growth Factor‐β: Multifunctional Regulator of Cell Growth and Phenotype

  1988cited by this paper
• Transforming growth factor-beta: multifunctional regulator of cell growth and phenotype.

  1988cited by this paper
• Growth regulation of human breast carcinoma occurs through regulated growth factor secretion

  1987cited by this paper
• Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines.

  1987cited by this paper

• The interaction of platelet-related factors with tumor cells promotes tumor metastasis

  2024cites this paper
• FGFR-related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review)

  2024cites this paper
• Organotropism of breast cancer metastasis: A comprehensive approach to the shared gene network

  2023cites this paper
• The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

  2022cites this paper
• Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer

  2021cites this paper
• Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor

  2021cites this paper
• Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44+CD24− Sorted MDA-MB-231 Cells by Cisplatin

  2021cites this paper
• Quantification of angiogenic factors and their clinicopathological associations in breast cancer

  2020cites this paper
• Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

  2020cites this paper
• What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review

  2020cites this paper
• THE ROLE OF NF-KB ACTIVATION IN BREAST CARCINOMA AND GLIOBLASTOMA CELL LINES by

  2019cites this paper
• PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors

  2018cites this paper
• Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis

  2018cites this paper
• Simvastatin down-regulates differential genetic profiles produced by organochlorine mixtures in primary breast cell (HMEC).

  2017cites this paper
• Applications of Platelet-Rich Plasma in Lymphedema

  2017cites this paper
• Involvement of PDGF ligands and receptors in tumorigenesis

  2017cites this paper
• Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

  2016cites this paper
• TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

  2016cites this paper
• Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases

  2016cites this paper
• Breast reconstruction with autologous fat graft; does platelet-rich plasma affect patient's survival?

  2014cites this paper
• Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma

  2014cites this paper
• Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment

  2014cites this paper
• Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors

  2014cites this paper
• OP0001 Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR2 inhibitor in metastatic breast cancer

  2014cites this paper
• Platelet-Rich Plasma in Surgical Oncology

  2014cites this paper
• Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy

  2014cites this paper
• Platelet-derived Growth Factor β-Receptor, Transforming Growth Factor β Type I Receptor, and CD44 Protein Modulate Each Other's Signaling and Stability*

  2014cites this paper
• Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer

  2014cites this paper
• Modulation of the biologic behaviour of breast cancer; in vitro models and clinical correlates

  2014cites this paper
• Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.

  2013cites this paper
• Targeting the PDGF signaling pathway in tumor

  2013cites this paper
• Tumor angiogenesis and anti-angiogenic therapies

  2013cites this paper
• Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment

  2013cites this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cites this paper
• Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.

  2013cites this paper
• Dietary supplementation with curcumin enhances metastatic growth of Lewis lung carcinoma in mice

  2012cites this paper
• Autocrine PDGF stimulation in malignancies

  2012cites this paper
• A New Mouse Model for the Study of Human Breast Cancer Metastasis

  2012cites this paper
• Understanding the Role of Stromal PTEN Regulated miR-101 and miR-130b in Tumor Microenvironment

  2012cites this paper
• Pazopanib for the treatment of breast cancer

  2012cites this paper
• Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice

  2012cites this paper
• Effects of non-motorized voluntary running on experimental and spontaneous metastasis in mice.

  2011cites this paper
• In silico Analysis of Combinatorial microRNA Activity Reveals Target Genes and Pathways Associated with Breast Cancer Metastasis

  2011cites this paper
• Anti‐stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model

  2011cites this paper
• New perspectives: role of Sunitinib in breast cancer.

  2011cites this paper
• Platelet-derived growth factor signaling in human malignancies

  2011cites this paper
• The role of platelet-derived growth factor in radiation injury to the lower urinary tract

  2011cites this paper
• Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy

  2010cites this paper
• Tumor angiogenesis and novel antiangiogenic strategies

  2010cites this paper
• Expression and prognostic value of platelet‐derived growth factor‐AA and its receptor α in nephroblastoma

  2010cites this paper
• The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer

  2010cites this paper
• New perspectives: role of sunitinib in breast cancer.

  2010cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 527 Combination Therapies Targeting PDGF and VEGF Signaling Pathways in Solid Tumors

  2010cites this paper
• Identification and Investigations of Leucine-rich Repeats and Immunoglobulin- like Domains Protein 2 (LRIG2)

  2010cites this paper
• Identification and Investigations of Leucine-rich Repeats and Immunoglobulin-like Domains Protein 2 ( LRIG 2 )

  2010cites this paper
• A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

  2010cites this paper
• PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?

  2009cites this paper
• Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.

  2009cites this paper
• PDGFRα: a new therapeutic target in the treatment of hepatocellular carcinoma?

  2009cites this paper
• An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

  2009cites this paper
• Serum Insulin-Like Growth Factor-I and Platelet-Derived Growth Factor as Biomarkers of Breast Cancer Prognosis

  2008cites this paper
• Betsholtz Role of platelet-derived growth factors in physiology and medicine

  2008cites this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cites this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cites this paper
• Decreased Parietal Cortex Activity during Mental Rotation in Children with Congenital Hypothyroidism

  2008cites this paper
• Breast cancer secreted factors alter the bone microenvironment

  2007cites this paper
• Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases

  2007cites this paper
• Role of Adrenomedullin in Breast Cancer Bone Metastasis and Chemoresistance

  2007cites this paper
• Possible predictive markers related to micro-metastasis in breast cancer patients.

  2006cites this paper
• Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy.

  2006cites this paper
• Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.

  2006cites this paper
• (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

  2005cites this paper
• Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.

  2005cites this paper
• Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

  2004cites this paper
• Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

  2004cites this paper
• Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma

  2004cites this paper
• Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

  2004cites this paper
• Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice

  2004cites this paper
• Novel pharmacological approaches in the treatment of breast cancer

  2003cites this paper
• Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.

  2003cites this paper
• Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.

  2002cites this paper
• Receptor Tyrosine Kinases in Angiogenesis

  2002cites this paper
• Expression of Melanoma Antigen-Encoding Gene-1 Predicts Lymph Node Involvement in Early Gastric Carcinomas

  2001cites this paper
• Antibody-Based targeting of angiogenesis.

  2001cites this paper
• The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.

  2000cites this paper
• SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

  2000cites this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cites this paper
• Design of growth factor antagonists with antiangiogenic and antitumor properties

  2000cites this paper
• Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.

  2000cites this paper
• Uptake of 125I-PDGF-AB to the blood after extravascular administration in mice.

  1998cites this paper
• Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

  1997cites this paper
• Sequential alpha-interferon and tamoxifen.

  1997cites this paper
• Insulin-like growth factor-I is an osmoprotectant in human neuroblastoma cells.

  1997cites this paper
• A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.

  1997cites this paper
• Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

  1997cites this paper
• Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.

  1996cites this paper
• Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma.

  1996cites this paper
• Plasma Platelet-Derived Growth Factor: Preliminary Study of a Potential Marker in Head and Neck Cancer

  1996cites this paper
• Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

  1995cites this paper